LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Risk factors associated with COVID-19 in systemic lupus erythematosus: Results from a longitudinal prospective cohort.

    Patil, Abhishek / Shobha, Vineeta / Shenoy, Padmanabha / S, Chandrashekara / Kumar, Sharath / Daware, Manisha / Haridas, Vikram / Janardana, Ramya / Pinto, Benzeeta / Kodishala, Chanakya / Ramaswamy, Subramanian / S, Nagaraj / Jain, Vikramraj / Singh, Yogesh Preet / Singhai, Shweta / C, Srinivasa / Jois, Ramesh / Rao, Vijay K / Dharmapalaiah, Chethana /
    Kn, Sangeetha / Balebail, Dharmanand

    Lupus

    2023  Volume 32, Issue 4, Page(s) 560–564

    Abstract: Introduction: Patients with SLE (systemic lupus erythematosus) have a higher risk of infection due to dysregulated immune system as well as long-term use of immunosuppressants (IS). This could influence the risk of COVID-19 and its outcome.: Methods: ...

    Abstract Introduction: Patients with SLE (systemic lupus erythematosus) have a higher risk of infection due to dysregulated immune system as well as long-term use of immunosuppressants (IS). This could influence the risk of COVID-19 and its outcome.
    Methods: We conducted a longitudinal prospective study across 15 rheumatology centres during the first wave of the pandemic to understand the risk factors contributing to COVID-19 in SLE patients. During the 6 months follow-up, those who tested positive for COVID-19, their clinical course and outcome information were recorded.
    Results: Through the study period (April-December 2020), 36/1379 lupus patients (2.9%) developed COVID-19. On analysing the COVID-19 positive versus negative cohort during the study period, male gender (adjusted RR 3.72, 95% C.I. 1.85,7.51) and diabetes (adjusted RR 2.94, 95% C.I. 1.28, 6.79) emerged as the strongest risk factors for COVID-19, in the adjusted analysis. There was no significant influence of organ involvement, hydroxychloroquine, glucocorticoid dosage (prednisolone< 7.5 mg or ≥ 7.5 mg/day) or IS on the risk of COVID-19. There was only one death (1/36) among the lupus patients due to COVID-19.
    Conclusion: Traditional risk factors rather than lupus disease process or IS influenced the risk of COVID-19 in our cohort.
    MeSH term(s) Humans ; Male ; Lupus Erythematosus, Systemic/complications ; Lupus Erythematosus, Systemic/drug therapy ; Prospective Studies ; COVID-19/complications ; Longitudinal Studies ; Immunosuppressive Agents/adverse effects ; Risk Factors
    Chemical Substances Immunosuppressive Agents
    Language English
    Publishing date 2023-02-02
    Publishing country England
    Document type Journal Article
    ZDB-ID 1154407-7
    ISSN 1477-0962 ; 0961-2033
    ISSN (online) 1477-0962
    ISSN 0961-2033
    DOI 10.1177/09612033231155837
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: A prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases.

    Patil, Abhishek / Chanakya, K / Shenoy, Padmanabha / Chandrashekara, S / Haridas, Vikram / Kumar, Sharath / Daware, Manisha / Janardana, Ramya / Pinto, Benzeeta / Subramanian, Ramaswamy / Nagaraj, S / Singh, Yogesh Preet / Singhai, Shweta / Jois, Ramesh / Jain, Vikramraj / Srinivasa, C / Dharmanand, B G / Dharmapalaiah, Chethana / Sangeetha, K N /
    Rao, Vijay K / Shobha, Vineeta

    BMC rheumatology

    2022  Volume 6, Issue 1, Page(s) 32

    Abstract: Background: We conducted this study to identify the influence of prolonged use of hydroxychloroquine (HCQ), glucocorticoids and other immunosuppressants (IS) on occurrence and outcome of COVID-19 in patients with autoimmune rheumatic diseases (AIRDs).!## ...

    Abstract Background: We conducted this study to identify the influence of prolonged use of hydroxychloroquine (HCQ), glucocorticoids and other immunosuppressants (IS) on occurrence and outcome of COVID-19 in patients with autoimmune rheumatic diseases (AIRDs).
    Methods: This was a prospective, multicenter, non-interventional longitudinal study across 15 specialist rheumatology centers. Consecutive AIRD patients on treatment with immunosuppressants were recruited and followed up longitudinally to assess parameters contributing to development of COVID-19 and its outcome.
    Results: COVID-19 occurred in 314 (3.45%) of 9212 AIRD patients during a median follow up of 177 (IQR 129, 219) days. Long term HCQ use had no major impact on the occurrence or the outcome of COVID-19. Glucocorticoids in moderate dose (7.5-20 mg/day) conferred higher risk (RR = 1.72) of infection. Among the IS, Mycophenolate mofetil (MMF), Cyclophosphamide (CYC) and Rituximab (RTX) use was higher in patients with COVID 19. However, the conventional risk factors such as male sex (RR = 1.51), coexistent diabetes mellitus (RR = 1.64), pre-existing lung disease (RR = 2.01) and smoking (RR = 3.32) were the major contributing risk factors for COVID-19. Thirteen patients (4.14%) died, the strongest risk factor being pre-existing lung disease (RR = 6.36, p = 0.01). Incidence (17.5 vs 5.3 per 1 lakh (Karnataka) and 25.3 vs 7.9 per 1 lakh (Kerala)) and case fatality (4.1% vs 1.3% (Karnataka) and 4.3% vs 0.4% (Kerala)) rate of COVID-19 was significantly higher (p < 0.001) compared to the general population of the corresponding geographic region.
    Conclusions: Immunosuppressants have a differential impact on the risk of COVID-19 occurrence in AIRD patients. Older age, males, smokers, hypertensive, diabetic and underlying lung disease contributed to higher risk. The incidence rate and the case fatality rate in AIRD patients is much higher than that in the general population.
    Language English
    Publishing date 2022-06-14
    Publishing country England
    Document type Journal Article
    ZDB-ID 2918121-5
    ISSN 2520-1026 ; 2520-1026
    ISSN (online) 2520-1026
    ISSN 2520-1026
    DOI 10.1186/s41927-022-00264-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top